Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| VTL | Vital Therapies, Inc. | 1.50% | 13.51 | 3.3% | $792.68m | |
| AMGN | Amgen Inc. | 2.36% | 204.02 | 1.3% | $749.47m | |
| GILD | Gilead Sciences, Inc. | 0.43% | 63.14 | 0.9% | $384.23m | |
| CELG | Celgene Corporation | 1.53% | 94.74 | 1.3% | $360.74m | |
| ILMN | Illumina, Inc. | 0.49% | 286.17 | 3.5% | $321.19m | |
| BIIB | Biogen Inc. | 1.78% | 231.68 | 1.3% | $305.34m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 2.11% | 184.94 | 1.9% | $260.38m | |
| EXAS | Exact Sciences Corporation | 1.35% | 119.82 | 24.1% | $245.81m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 1.66% | 110.85 | 2.0% | $238.74m | |
| REGN | Regeneron Pharmaceuticals, Inc. | 1.28% | 296.85 | 2.6% | $212.35m | |
| A | Agilent Technologies, Inc. | 2.18% | 71.11 | 1.6% | $206.33m | |
| SRPT | Sarepta Therapeutics, Inc. | 2.44% | 124.95 | 14.7% | $156.17m | |
| INCY | Incyte Corporation | 3.11% | 83.12 | 2.5% | $97.22m | |
| BMRN | BioMarin Pharmaceutical Inc. | 6.65% | 76.50 | 4.3% | $91.98m | |
| SGEN | Seattle Genetics, Inc. | 3.25% | 79.20 | 6.5% | $90.21m |
Company Profile
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.